scholarly journals Cell Clearing Systems as Targets of Polyphenols in Viral Infections: Potential Implications for COVID-19 Pathogenesis

Antioxidants ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 1105
Author(s):  
Fiona Limanaqi ◽  
Carla Letizia Busceti ◽  
Francesca Biagioni ◽  
Gloria Lazzeri ◽  
Maurizio Forte ◽  
...  
Keyword(s):  
Viral Infections ◽  
Multiple Organ ◽  
Pharmacological Therapy ◽  
The Novel ◽  
Therapeutic Approaches ◽  
Beneficial Effects ◽  
Anti Oxidant ◽  
Neurological Alterations ◽  
Novel Coronavirus ◽  
Coagulation Dysfunction

The novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has generated the ongoing coronavirus disease-2019 (COVID-19) pandemic, still with an uncertain outcome. Besides pneumonia and acute lung injury (ALI) or acute respiratory distress syndrome (ARDS), other features became evident in the context of COVID-19. These includes endothelial and coagulation dysfunction with disseminated intravascular coagulation (DIC), and multiple organ dysfunction syndrome (MODS), along with the occurrence of neurological alterations. The multi-system nature of such viral infection is a witness to the exploitation and impairment of ubiquitous subcellular and metabolic pathways for the sake of its life-cycle, ranging from host cell invasion, replication, transmission, up to a cytopathic effect and overt systemic inflammation. In this frame, alterations in cell-clearing systems of the host are emerging as a hallmark in the pathogenesis of various respiratory viruses, including SARS-CoV-2. Indeed, exploitation of the autophagy and proteasome pathways might contribute not only to the replication of the virus at the site of infection but also to the spreading of either mature virions or inflammatory mediators at both cellular and multisystem levels. In this frame, besides a pharmacological therapy, many researchers are wondering if some non-pharmacological substances might counteract or positively modulate the course of the infection. The pharmacological properties of natural compounds have gained increasing attention in the field of alternative and adjunct therapeutic approaches to several diseases. In particular, several naturally-occurring herbal compounds (mostly polyphenols) are reported to produce widespread antiviral, anti-inflammatory, and anti-oxidant effects while acting as autophagy and (immuno)-proteasome modulators. This article attempts to bridge the perturbation of autophagy and proteasome pathways with the potentially beneficial effects of specific phytochemicals and flavonoids in viral infections, with a focus on the multisystem SARS-CoV-2 infection.

scholarly journals Probiotics: relevant during the coronavirus (COVID-19) infection pandemic?

2022 ◽  
pp. 165-172
Author(s):  
M. A. Shevyakov
Keyword(s):  
Viral Infections ◽  
Therapeutic Potential ◽  
Severe Disease ◽  
The Body ◽  
Intestinal Damage ◽  
The Novel ◽  
Beneficial Effects ◽  
Treatment And Prevention ◽  
Acute Respiratory Diseases ◽  
Novel Coronavirus

The review presents modern views on the role of probiotics in the treatment and prevention of complications of the novel coronavirus COVID-19 infection. This infection can be complicated, for example, by the development of diarrhea after the use of antibacterial drugs in case of secondary bacterial infection, extrapulmonary viral infections, viremia, and the so-called «cytokine storm». The emphasis has been placed on such potentially beneficial effects of probiotics as а prevention of antibioticassociated diarrhea, prevention of intestinal damage induced directly by viral replication, prevention of leaky gut syndrome and immunomodulation in case of coronavirus COVID-19 infection. It has been shown that the use of probiotics alongside antibiotic therapy significantly reduces the risk of developing antibiotic-associated diarrhea, including such a severe variant as pseudomembranous colitis. The use of a probiotic during a viral respiratory disease reduces the risk of a severe disease course due to the positive modulation of inflammation and direct antiviral effects. Selected data showed the positive effect of probiotics on the tight junction stability of the intestine, which potentially protects against viremia and the penetration of immunogenic molecules into the internal environment of the body. In order to address the challenges adequately, a probiotic should meet certain requirements in terms of product quality, safety, evidence of efficacy, composition and understanding of the strains. The article presents data on the successful use of a multi-strain immuno-probiotic as an example demonstrating the therapeutic potential of modern multi-strain probiotics as a nonspecific immunomodulatory agent for the prevention of acute respiratory diseases.

scholarly journals POTENTIAL THERAPIES FOR TREATMENT OF COVID-19

2020 ◽  
Vol 7 (1) ◽  
pp. 062-071
Author(s):  
Beatriz Gasser ◽  
Ricardo Andres Ramirez Uscategui
Keyword(s):  
Clinical Trials ◽  
Distress Syndrome ◽  
Multiple Organ ◽  
The Novel ◽  
Controlled Clinical Trials ◽  
Interferon Β ◽  
The World ◽  
Novel Coronavirus ◽  
Time Point

Since discovery of the novel coronavirus (SARS-CoV-2) in December of 2019, this viral pneumonia originated in Wuhan, China quickly spread around the world. This new disease, called COVID-19 can cause Acute Respiratory Distress Syndrome (ARDS) due to an uncontrolled inflammatory response like sepsis, that leads to multiple organ failure and even death. Several pharmacotherapeutics alternatives are being tested over the world, looking for most diverse drugs that might be able to fight the infection. The objective of this paper is to review the main pharmacotherapeutics techniques development, as remdesivir, chloroquine/hydroxychloroquine, lopinavir plus ritonavir, interferon-β, ivermectin, anticoagulants, convalescent plasma and vaccine, currently undergoing clinical trials in order to evaluate its effectiveness and safety to combat the COVID-19, presenting their characteristics, possible adverse effects and main scientific findings of its potential action. In conclusion, some therapies presented promising in-vitro results or in the treatment of some patients, nonetheless, multicentric blinded placebo controlled clinical trials are necessary to determine their effectiveness, safety, dosage, and best time point of treatment.

scholarly journals Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?

2021 ◽  
Vol 12 ◽  
Author(s):  
Gianmarco Bellucci ◽  
Virginia Rinaldi ◽  
Maria Chiara Buscarinu ◽  
Roberta Reniè ◽  
Rachele Bigi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Viral Infections ◽  
Current Knowledge ◽  
Endogenous Retroviruses ◽  
The Novel ◽  
Barr Virus ◽  
Complex Interactions ◽  
The Central Nervous System ◽  
Epstein Barr ◽  
Novel Coronavirus

Current knowledge on Multiple Sclerosis (MS) etiopathogenesis encompasses complex interactions between the host’s genetic background and several environmental factors that result in dysimmunity against the central nervous system. An old-aged association exists between MS and viral infections, capable of triggering and sustaining neuroinflammation through direct and indirect mechanisms. The novel Coronavirus, SARS-CoV-2, has a remarkable, and still not fully understood, impact on the immune system: the occurrence and severity of both acute COVID-19 and post-infectious chronic illness (long COVID-19) largely depends on the host’s response to the infection, that echoes several aspects of MS pathobiology. Furthermore, other MS-associated viruses, such as the Epstein-Barr Virus (EBV) and Human Endogenous Retroviruses (HERVs), may enhance a mechanistic interplay with the novel Coronavirus, with the potential to interfere in MS natural history. Studies on COVID-19 in people with MS have helped clinicians in adjusting therapeutic strategies during the pandemic; similar efforts are being made for SARS-CoV-2 vaccination campaigns. In this Review, we look over 18 months of SARS-CoV-2 pandemic from the perspective of MS: we dissect neuroinflammatory and demyelinating mechanisms associated with COVID-19, summarize pathophysiological crossroads between MS and SARS-CoV-2 infection, and discuss present evidence on COVID-19 and its vaccination in people with MS.

scholarly journals Therapeutic approaches to tackle COVID-19: An overview

2021 ◽  
Vol 8 (2) ◽  
pp. 121-135
Author(s):  
Princy Louis Palatty ◽  
Rosme David ◽  
Belinda Mangalath Philip ◽  
Clint Sunny ◽  
Mamatha J ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Treatment Guidelines ◽  
World Health Organisation ◽  
Current Medical ◽  
World Health ◽  
Director General ◽  
The Novel ◽  
Therapeutic Approaches ◽  
Literature Searches ◽  
Novel Coronavirus

: A series of an acute atypical respiratory disease occurred during December 2019 in Wuhan, China, that quickly metamorphosed as a pandemic, spreading across the globe, leaving more than 104,911,186 infected and more than 2,278,579 dead, in its wake within a year. This Novel Coronavirus, was also called Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and the disease was called Coronavirus Disease 19 (COVID-19). On 30 January 2020, The World Health Organisation (WHO) Director-General, declared the novel coronavirus outbreak, a public health emergency of international concern and flagged off WHO's highest level of alarm.: To elaborate the various drug therapies used in trials and vaccines available for COVID-19 across the globe.: We compiled the literature searches under a single heading and scrutinized over 154 articles, for extracting data on the various pharmacotherapeutic approaches available to treat COVID-19.: Despite wide and varied treatment guidelines being available, the cure or prevention is still elusive for COVID-19. The categoric efficacy of vaccines must be proved to tackle the fast-mutating coronavirus.: Current medical management is largely supportive with no targeted therapy available. Several drugs including lopinavir-ritonavir, remdesivir, antibiotics, hydroxychloroquine, steroids, anticoagulants, and antidiabetic drugs like metformin have been tried in clinical trials. Vaccines targeting the three different components of SARS-CoV-2 viruses, in different phases of clinical trials world-wide, have been made available.

scholarly journals Pharmacotherapy for COVID-19: A Ray of Hope

2021 ◽  
Author(s):  
Mayank Kapoor ◽  
Prasan Kumar Panda ◽  
Vivek Mohanty
Keyword(s):  
Large Scale ◽  
Kinase Inhibitors ◽  
Viral Infections ◽  
Treatment Options ◽  
Interferon Alfa ◽  
The Novel ◽  
Plasma Therapy ◽  
Therapeutic Drugs ◽  
Novel Coronavirus ◽  
Multiple Drugs

Most viral infections have limited treatment options available and the same holds for COVID-19, its causative agent being the SARS-CoV-2 virus. Drugs used in the past against Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS) viruses, which belong to the same family of viruses as the novel Coronavirus included ribavirin, interferon (alfa and beta), lopinavir-ritonavir combination, and corticosteroids. There remains controversy regarding their efficacy to date, except for the last one. Hence, large-scale multicentric trials are being conducted involving multiple drugs. Chloroquine and hydroxy-chloroquine were initially taking the race ahead but have now been rejected. Remdesivir was a promising candidate, for which the FDA had issued an emergency use authorization, but now is not recommended by the WHO. Convalescent plasma therapy had promising results in the early severe viremia phase, but the PLACID trial made an obscure end. Only corticosteroids have shown demonstrable benefits in improving mortality rates among severe COVID-19 cases. Many new modalities like monoclonal antibodies and tyrosine kinase inhibitors are discussed. In this chapter, we review the therapeutic drugs under investigation for the COVID-19 treatment, their mode of action, degree of effectiveness, and recommendations by different centers regarding their use in current settings.

scholarly journals Food Containing Bioactive Flavonoids and Other Phenolic or Sulfur Phytochemicals With Antiviral Effect: Can We Design a Promising Diet Against COVID-19?

2021 ◽  
Vol 8 ◽  
Author(s):  
Martina Ghidoli ◽  
Federico Colombo ◽  
Stefano Sangiorgio ◽  
Michela Landoni ◽  
Luca Giupponi ◽  
...  
Keyword(s):  
Rational Design ◽  
Complementary Therapy ◽  
Antiviral Effect ◽  
The Novel ◽  
Therapeutic Approaches ◽  
Degree Of Protection ◽  
Global Pandemic ◽  
Cultivated Plant ◽  
Novel Coronavirus ◽  
Inflammatory Action

Since in late 2019, when the coronavirus 2 (SARS-CoV-2) pathogen of coronavirus disease 2019 (COVID-19) started to spread all over the world, causing the awful global pandemic we are still experiencing, an impressive number of biologists, infectious disease scientists, virologists, pharmacologists, molecular biologists, immunologists, and other researchers working in laboratories of all the advanced countries focused their research on the setting up of biotechnological tools, namely vaccines and monoclonal antibodies, as well as of rational design of drugs for therapeutic approaches. While vaccines have been quickly obtained, no satisfactory anti-Covid-19 preventive, or therapeutic approach has so far been discovered and approved. However, among the possible ways to achieve the goal of COVID-19 prevention or mitigation, there is one route, i.e., the diet, which until now has had little consideration. In fact, in the edible parts of plants supplying our food, there are a fair number of secondary metabolites mainly belonging to the large class of the flavonoids, endowed with antiviral or other health beneficial activities such as immunostimulating or anti-inflammatory action that could play a role in contributing to some extent to prevent or alleviate the viral infection and/or counteract the development of SARS induced by the novel coronavirus. In this review, a number of bioactive phytochemicals, in particular flavonoids, proven to be capable of providing some degree of protection against COVID-19, are browsed, illustrating their beneficial properties and mechanisms of action as well as their distribution in cultivated plant species which supply food for the human diet. Furthermore, room is also given to information regarding the amount in food, the resistance to cooking processes and, as a very important feature, the degree of bioavailability of these compounds. Concluding, remarks and perspectives for future studies aimed at increasing and improving knowledge and the possibility of using this natural complementary therapy to counteract COVID-19 and other viral pathologies are discussed.

scholarly journals Kidney damage by COVID-19 and rationale for extracorporeal therapies

2020 ◽  
Vol 7 (10) ◽  
pp. 4071-4074
Author(s):  
Uzma Mehreen ◽  
Ashiq Ali ◽  
Aisha Khatoon ◽  
Nishat Zafar ◽  
Qaisar Tanveer ◽  
...  
Keyword(s):  
Human Body ◽  
Multiple Organ ◽  
Blood Purification ◽  
Kidney Damage ◽  
The Novel ◽  
Kidney Involvement ◽  
Novel Coronavirus ◽  
Extracorporeal Support ◽  
Organ Dysfunctions

Without doubt, there is some involvement of the kidney in novel coronavirus disease (COVID-19), which is responsible for multiple organ dysfunctions resulting in severe complications in the human body. This newly discovered COVID-19 has incited panic globally. However, the role of kidney involvement in the novel COVID-19 disease is still unclear. In this commentary, we discuss the various pathways involved in kidney damage by COVID-19, and the rationale for extracorporeal support with various blood purification strategies in critically ill people with COVID 19.

scholarly journals Role of nutrients regulation in the immune system in preventing COVID-19 infection: A brief review

2021 ◽  
Vol 13 (2) ◽  
pp. 760-765
Author(s):  
Anamika Chauhan
Keyword(s):  
Immune System ◽  
Age Groups ◽  
World Health ◽  
The Novel ◽  
Beneficial Effects ◽  
Coronavirus Infection ◽  
The Common ◽  
Novel Coronavirus ◽  
Health Organization

This review aimed to focus on using foods to boost immunity against COVID-19 in all age groups. In human, coronavirus causes the common cold, severe acute respiratory syndrome (SARS), and a major threat to public health. The novel coronavirus was declared a pandemic by the World Health Organization due to its rapid infectivity. COVID-19 infection is most probably reported in people with low immunity response. The nutrients, which show beneficial effects on the immune system, are called immune nutrients and diet is called immune diet. A healthy diet can reduce the risk of infection of COVID-19 and can prevent disease. Nutritional food intake is also necessary for people with chronic illness, obese persons, diabetes, cardiovascular disease, cognitive dysfunction like anxiety and depression. All nutrients are essential for maintaining immunity and providing appropriate amounts of protein, fat, carbohydrate, vitamins, and minerals for the surveillance mode of keeping us from getting sick. The use of plenty of water, minerals such as micronutrients, zinc, copper, selenium, iron, magnesium, food rich in vitamins, and a good lifestyle can promote health and overwhelm this coronavirus infection.

scholarly journals Acute respiratory infections in outpatient care in the era of the COVID-19 pandemic: the role and position of antibacterial therapy

2020 ◽  
Vol 4 (4) ◽  
pp. 214-218
Author(s):  
R.F. Khamitov ◽  
Keyword(s):  
Health Care ◽  
Outpatient Care ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Respiratory Viruses ◽  
Acute Respiratory Infections ◽  
The Novel ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Care Costs

Acute respiratory infections of the upper and lower respiratory tract are currently the leading cause of human morbidity, mainly due to the seasonal rise of the incidence rates of viral infections. This results in the heavy burden of annual health care costs. The COVID-19 pandemic exacerbated the problem. The associations between respiratory viruses and bacteria are not always clear thus accounting for the diversity of the risks of the complicated course and fatal outcomes of various bacterial viral coinfections. Influenza virus is associated with the high rate of bacterial complications (in particular, during seasonal peaks). Meanwhile, this is less typical of the novel coronavirus infection. In addition, several studies demonstrate the competitive edge of SARS-CoV-2 when interacting with other respiratory viruses. The specificities of viral bacterial associations greatly affect the treatment whose inadequacy (in particular, the prescription of antibiotics) is the leading cause of the increasing antimicrobial resistance of contemporary germs. The novel coronavirus infection SARS-CoV-2 is no exception in terms of inappropriate antibiotic prescribing as occurred often in the seasonal rise of acute respiratory viral infections. The understanding of this issue, the optimization of treatment strategies, and a reduction in health care costs will allow for preserving antibiotics as a class of highly effective medications. KEYWORDS: acute respiratory infections, COVID-19, bacterial coinfection, outpatient care, lung damage, antimicrobial therapy. FOR CITATION: Khamitov R.F. Acute respiratory infections in outpatient care in the era of the COVID-19 pandemic: the role and position of antibacterial therapy. Russian Medical Inquiry. 2020;4(4):214–218. DOI: 10.32364/2587-6821-2020-4-4-214-218.

Sign in / Sign up

Export Citation Format

Share Document